Uterine fibroids, cervical cancer
Conditions
Interventions
butorphanol group (Group B):butorphanol
Tegileridine group (Group T):Tegileridine
Sponsors
Jinan Maternal and Child Health Care Hospital
Eligibility
Sex/Gender
Female
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1.ASA physical status I–III; 2.Aged 18–65 years; 3.BMI 18–30 kg/m²; 4.Willing to participate voluntarily in this study; 5.No severe cardiac or pulmonary disease;
Exclusion criteria
Exclusion criteria: 1.Chronic pain; 2.History of psychiatric disorders; 3.History of long-term opioid use; 4.Patients with acute or severe bronchial asthma; 5.Patients with known hypersensitivity to opioids. 6.Patients with severe hepatic or renal insufficiency; 7.Patients with acute intestinal obstruction; 8.Patients with acute intestinal perforation; 9.Long-term use of anxiolytics, antipsychotics, or antidepressants;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Record resting NRS scores; | — |
Secondary
| Measure | Time frame |
|---|---|
| Time to first rescue analgesi;Record resting and dynamic NRS scores;Incidence of adverse events (pruritus, respiratory depression, nausea, vomiting, urinary retention);QoR-15 (15-item Quality of Recovery Scale), Ramsay Sedation Score, and sleep-quality satisfaction score ; | — |
Countries
China
Contacts
Public ContactYanan Liang
Jinan Maternal and Child Health Care Hospital
Outcome results
None listed